FR
EN- A-
- A+
Research & Innovation
Innovation, a key for the development of Théa
A continued innovation process and a unique expertise, 100% dedicated to ophthalmology.
Surgery techniques and therapeutic approaches evolve very quickly with the latest discoveries in pathophysiology, biotechnology and genetics. These advances will also bring new ophthalmic treatments. In this context, Théa continues to invest in R&D to stay at the forefront of innovation and be a pioneer in the new generations of products.
Our Strategic trends of development
Since its creation, less than thirty years ago, Théa has been known for its numerous innovations. The strategy of Laboratoires Théa in R & D is focused on three areas of development:
■ Innovative drug delivery systems
■ Development of new molecules for ophthalmic use
■ Improvement of existing products through galenic development
Externationalisation An original research approach
To avoid structural obstacles and remain at the leading edge of progress, Théa has made externalisation one of its R&D strategic pillars.
Confidential and high added value tasks and procedures remain internal. Preclinical (pharmacology, pharmacocinetics, toxicology) and clinical trials are subcontracted. This approach means that we have systematic access to the best international teams and experts for each discipline and subject.
Our Partnerships
Théa is committed to the construction of strong, sustainable partnerships, signing licensing agreements with researchers, universities and pharmaceutical or biotechnological companies.
Théa is also a welcoming structure particularly suited to support inventors in their process of recovery and protection of their research (patents, know-how transfer).
Our Quality
Théa meets the highest level of regulatory requirements and applies them on an international level. It has approved Pharmaceutical Facility status in compliance with European Good Manufacturing Practices and is also ISO 13485.
This proved excellence enables our products to be registered in many countries, including those with the highest level of requirements (Europe, Japan, USA). Over the years, it has given Théa significant expertise relative to regulations and international registration.
